CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (“Dicerna”), announced today the commencement of a proposed underwritten public offering of 2,750,000 shares of common stock. Dicerna also intends to grant the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Help employers find you! Check out all the jobs and post your resume.